ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
On behalf of the Board of Directors, I am honored to have recently joined the ProMIS management team as the interim CEO to steer the company through what we believe will be an exciting and informative ...
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. 22, ...
ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...
Hosted on MSN
ProMIS Neurosciences Announces Reverse Stock Split
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results